Subject: A survey among dermatologist to understand usage pattern of Levocetirizine updosing in chronic spontaneous urticaria (CSU) in India
Chronic Spontaneous Urticaria (CSU) is a dermatological condition characterized by recurrent transient wheals, with or without angioedema, occurring daily or almost daily for more than six weeks. The recurrent symptoms often result in sleep disturbances and cause notable negative impacts on quality of life. Antihistamines form the first-line treatment for this condition, and non-sedative second-generation antihistamines are recommended due to their minimal anti-cholinergic, sedative, and drug-interacting properties and longer half-lives.
However, almost 60 percent of patients remain uncontrolled with the standard licensed dose second generation non-sedating anti-histaminic. In this subset of patients, up-dosing of second generation non-sedating anti-histaminic up to four times the licensed dose has been recommended by most guidelines.
Data suggests increasing the daily dose of second generation antihistamine, Levocetirizine to up to 4 times its conventionally prescribed doses of 5 mg/d increases the control of urticaria symptoms without compromising patient safety.
This survey is conducted among dermatologist to understand usage pattern of Levocetirizine updosing in CSU in India.
As you will be spending some extra time to give your feedback on the questionnaire based on your clinical experience, we offer to pay you by cheque a professional fee of Rs {{$contractAmount}}, on receiving the completed Survey Questionnaire Form from you.
We trust you and we are partners in promoting safe and effective drug therapy. In that spirit we hope you will consent to participate in this study. If you do, please sign and return the enclosed reply along with your visiting card for accuracy of records.
|
}}){kind=logo}
}})